SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — David Hume

PatientDavid Hume
Date of birth1962-05-07
IdentifiersMRN HR-EN012-SYN; SSN (made up) 000-12-3049
Document date2026-10-19
AuthorFiona Gallacher, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review after completing adjuvant chemotherapy; start of surveillance. [S]

History of Present Illness

Mr. Hume returns two weeks after the last capecitabine dose of his fourth and final CAPOX cycle. The DPYD genotype before cycle 1 showed no decreased-function variant, and he received all four cycles on schedule at full dose. In cycle 2 he had three days of loose stools, controlled with loperamide. His September cold resolved without complications. Cold-triggered tingling after each oxaliplatin dose has left mild numbness of the fingertips and toe tips that does not interfere with buttoning, writing, or walking, and is not painful. He has no bowel bleeding or change in habit, no abdominal pain, cough, or bone pain. He walks 30 minutes a day and writes every morning. He feels well and asks what the follow-up will be. [S]

ElementDetail
TreatmentFour cycles of CAPOX completed at full dose
ToxicityGrade 1 diarrhea in cycle 2; grade 1 sensory neuropathy; no hand-foot syndrome
Recurrence symptomsNone: no bleeding, change in bowel habit, pain, cough, or weight loss
FunctionWalking 30 minutes a day; writing daily
Weight81.0 kg, down 1.5 kg since the postoperative visit

Review of Systems

SystemResultFinding
ConstitutionalPositiveMild tiredness in the afternoons; no fever or night sweats
GastrointestinalNegativeFormed stools once or twice a day; no blood or pain
RespiratoryNegativeNo cough or breathlessness
MusculoskeletalNegativeNo bone pain
NeurologicalPositiveNumb fingertips and toe tips, not painful; no weakness or imbalance
PsychiatricNegativeMood good; PHQ-2 score 0

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferric carboxymaltose 750 mg intravenous infusion, two doses one week apart750 mg IV once a week for two dosesIntravenous route2026-06-01 to 2026-06-08completedS
Capecitabine 500 mg oral tablet, four tablets (2000 mg, 1000 mg/m²) by mouth twice daily on days 1 to 14 of each 21-day cycle, four cyclesFour tablets twice daily on days 1 to 14 of each 21-day cycleOral route2026-07-20 to 2026-10-04completedS
Oxaliplatin 130 mg/m² (260 mg) intravenous infusion on day 1 of each 21-day cycle, four cycles260 mg IV on day 1 every 21 daysIntravenous route2026-07-20 to 2026-09-21completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea during chemotherapyOne tablet every 8 hours as needed for nauseaOral route2026-07-20 to 2026-10-04completedS
Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than eight a dayAs needed for diarrhea on capecitabineOral route2026-07-20 to 2026-10-04completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-19Body height178cmS
2026-10-19Body weight81kgS
2026-10-19Body mass index (BMI) [Ratio]25.6kg/m2S
2026-10-19Systolic blood pressure122mm[Hg]S
2026-10-19Diastolic blood pressure74mm[Hg]S
2026-10-19Heart rate76/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-19Carcinoembryonic Ag [Mass/volume] in Serum or Plasma1.8ng/mL<=3 ng/mLNormalS
2026-10-19Hemoglobin [Mass/volume] in Blood12.8g/dL13.2-16.6 g/dLLowS
2026-10-19MCV [Entitic mean volume] in Red Blood Cells by Automated count89fL80-100 fLNormalS
2026-10-19Leukocytes [#/volume] in Blood by Automated count5.210*3/uL4-11 10*3/uLNormalS
2026-10-19Neutrophils [#/volume] in Blood by Automated count2.910*3/uL1.5-7.7 10*3/uLNormalS
2026-10-19Platelets [#/volume] in Blood by Automated count12810*3/uL150-400 10*3/uLLowS
2026-10-19Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.74-1.35 mg/dLNormalS
2026-10-19Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M93mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-55 U/LNormalS
2026-10-19Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
2026-10-19Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]

SystemFinding
GeneralWell
AbdomenScars healed; soft; no mass or liver enlargement
Lymph nodesNo supraclavicular or inguinal nodes
NeurologicalReduced light touch at the fingertips and toe tips; vibration slightly reduced at the toes; proprioception, strength, ankle reflexes, and Romberg normal
SkinPalms and soles normal

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the sigmoid colon, suspected at presentation and confirmed by colonoscopic biopsy; synthetic modern diagnosis linked to the documented 1775 bowel disorder and its retrospective interpretation as colon canceractiveconfirmed C18.7S — Synthetic diagnosis confirmed by biopsy and resection in the modern episode; the historical diagnosis remains a retrospective interpretation (R).
Iron deficiency anemia from chronic blood loss from the colon tumoractiveconfirmed D50.0S — Synthetic finding echoing the documented 'hemorrhage in the upper part of the intestines'; no blood count from his lifetime exists.
Hemangioma of the liver, 9 mm, segment VI; incidental finding characterized by MRI, not a metastasisactiveconfirmed D18.03S — Synthetic incidental finding; it addresses, and does not confirm, the unverified suggestion of liver spread.
Acute viral upper respiratory infection during adjuvant chemotherapy, without fever or neutropenia; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.
Oxaliplatin-induced sensory peripheral neuropathy, grade 1, fingertips and toe tips, without functional impairmentactiveconfirmed G62.0S — Synthetic expected toxicity of adjuvant oxaliplatin.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryCEAEvery 3 to 6 months for 2 years, then every 6 months to 5 yearsCompleted today1.8 ng/mL, normal
LaboratoryBlood count after chemotherapyAt the end of treatmentCompleted todayHemoglobin 12.8 g/dL, MCV 89 fL, white cells 5.2, neutrophils 2.9, platelets 128
LaboratoryKidney and liver functionAt the end of treatmentCompleted todayCreatinine 0.92 mg/dL, eGFR 93; ALT 31 U/L, bilirubin 0.7 mg/dL
ExaminationHistory and physical examinationEvery 3 to 6 months for 2 yearsCompleted todayNo evidence of recurrence
ExaminationPeripheral neuropathy (CIPN)Every visit during and after oxaliplatinCompleted todayGrade 1 sensory neuropathy, not painful
SurveyDistress and depression screen (PHQ-2)At each follow-up visitCompleted todayPHQ-2 score 0
SurveyFatigueEvery visitCompleted todayMild afternoon tiredness; activity advised
ImagingCT of the chest, abdomen, and pelvisEvery 6 to 12 months for 5 yearsDueIn December, six months after surgery
ExaminationSurveillance colonoscopyOne year after resection, then at three years, then every five yearsDueIn June; the preoperative colonoscopy was complete
Medication safetyDuloxetine for painful neuropathyIf neuropathy is painfulNot indicatedNeuropathy is not painful
ReferralGenetic counselingOnceDueAppointment next month, after chemotherapy as he asked
Self-managementSurvivorship care plan and lifestyle counselingWithin one year of treatment completion; lifestyle every visitCompleted todayWritten plan given; 150 minutes of activity a week, a diet low in red and processed meat, alcohol at or below one drink a day

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, Version 4.2025 (2025); The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer (2021); American Cancer Society Colorectal Cancer Survivorship Care Guidelines (2015); CMID: Clinical Monitoring Intelligence Database, colorectal cancer and anemia monographs (2026)

Follow-up: Adult preventive visit later this month. CT in December. Surveillance visit with CEA and blood count in January. Next scheduled visit 2026-10-28: adult preventive visit. [S]